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The fatty acid synthesis type II pathway has received
considerable interestasacandidate therapeutic target
in Plasmodium falciparum asexual blood-stage infec-
tions. This apicoplast-resident pathway, distinct from
the mammalian type I process, includes FabI. Here,
we report synthetic chemistry and transfectionstudies
concluding that Plasmodium FabI is not the target of
the antimalarial activity of triclosan, an inhibitor of bac-
terial FabI. Disruption of fabI inP. falciparum or the ro-
dent parasiteP. berghei does not impede blood-stage
growth. In contrast, mosquito-derived, FabI-deficient
P. berghei sporozoites are markedly less infective for
mice and typically fail to complete liver-stagedevelop-
ment in vitro. This defect is characterized by an inabil-
ity to form intrahepatic merosomes that normally
initiate blood-stage infections. These data illuminate
key differences between liver- and blood-stage para-
sites in their requirements for host versus de novo
synthesized fatty acids, and create new prospects
for stage-specific antimalarial interventions.
INTRODUCTION
Plasmodium parasites must coordinate the salvage of host
factors with de novo biosynthesis pathways in order to meetCell Hostthe unique demands of each intracellular stage of their life cycle.
In mammals, this begins with the bite of an infected Anopheles
mosquito. The intradermally injected sporozoites (SPZs) then
migrate to the liver and invade hepatocytes (Amino et al., 2008).
Liver-stage development involves the transformation of an intra-
cellular sporozoite, bounded by an inner parasite plasma mem-
brane (PPM) and an outer parasitophorous vacuolar membrane
(PVM), into a liver-stage trophozoite. This stage undergoes pro-
lific nuclear division and membrane synthesis, with commensu-
rate metabolic demands. In the case of P. falciparum, the most
lethal etiologic agent of human malaria, each infected hepatocyte
produces up to 10,000–30,000 merozoites, contained within an
intrahepatic merosome, over 6–7 days.
Liberated liver-stage merozoites enter the bloodstream, where
they invade red blood cells (RBCs) and initiate the asexual blood
stages that cause clinical manifestations of disease. Parasite
development inside these anucleate cells displays several funda-
mental differences from the liver stages (Silvie et al., 2008b).
These include the ability of asexual blood-stage parasites to
degrade hemoglobin and detoxify heme (processes that are
key to the mode of action of multiple antimalarials), and also to
modify the host cell membrane, such that the infected RBCs
can sequester in the microvasculature. The entire asexual cycle
is completed within 48 hr, producing 8–24 infectious merozoites
per infected RBC. In contrast to the small liver-stage inoculum,
numbers of infected RBCs can exceed 1012 per host (Greenwood
et al., 2008). Intraerythrocytic parasites can also transform into
sexual gametocyte stages. Upon their ingestion by a feeding
Anopheles mosquito, these parasites undergo fertilization and& Microbe 4, 567–578, December 11, 2008 ª2008 Elsevier Inc. 567
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migrate to the salivary glands, ready to initiate a new round of
infection.
The prodigious proliferative capacity of malarial parasites
necessitates access to an abundant source of fatty acids (FAs).
These carboxylic acid-linked acyl chains are required for the pro-
duction of lipid species that are essential for parasite membrane
and lipid body biogenesis (Palacpac et al., 2004). FAs are also re-
quired for glycosylphosphatidylinositol (GPI) moieties that serve
to anchor parasite membrane proteins (Gilson et al., 2006). FA
and phospholipid concentrations are, respectively, 6-fold and
3- to 5-fold higher in infected compared to uninfected RBCs.
This was initially attributed to FA salvage from host plasma, as
parasites were thought to be incapable of de novo synthesis
(Vial and Ancelin, 1992). The paradigm changed with the discov-
ery thatP. falciparum harbors components of a type II FA biosyn-
thesis (FAS-II) pathway (Ralph et al., 2004). A subsequent study
reported that P. falciparum asexual blood stages had FAS-II ac-
tivity, producing FAs with chain lengths of C10–C14 (Surolia and
Surolia, 2001). FAS-II enzymes have been localized to the apico-
plast, a nonphotosynthetic plastid organelle of cyanobacterial
origin. In addition to FA biosynthesis, the apicoplast harbors
unique pathways for the synthesis of isoprenoids and heme and
shares lipoic acid synthesis and salvage pathways with the
mitochondria. The discovery that antibiotics with antimalarial ac-
tivity inhibit apicoplast function has highlighted the therapeutic
potential of targeting this organelle (Ralph et al., 2004).
The FAS-II pathway inPlasmodium has been of particular ther-
apeutic interest, because it is distinct from the type I (FAS-I)
pathway found in mammals. FAS-II requires acetyl-Coenzyme A
(CoA), which can be converted from pyruvate by the pyruvate
dehydrogenase complex. Acetyl-CoA carboxylase converts
acetyl-CoA to malonyl-CoA, which is tethered to an acyl carrier
protein (ACP) by malonyl-CoA:ACP transacylase (FabD). This
produces malonyl-ACP, which, in conjunction with acetyl-CoA,
is acted upon by b-ketoacyl-ACP synthase III (Fab H) to form
b-ketoacyl-ACP. This precursor enters the FAS-II elongation cy-
cle, mediated by FabB/F (b-ketoacyl-acyl-carrier-protein (ACP)
synthase), FabG (b-ketoacyl-ACP reductase), FabZ/A (b-hydrox-
yacyl-ACP dehydratase), and FabI (trans-2-enoyl-ACP reduc-
tase). These four FAS-II enzymes iteratively catalyze the addition
of two carbon chains to a growing fatty acyl carbon chain via
condensation, reduction, dehydration, and reduction steps,
respectively. In contrast, FAS-I contains all four enzymatic func-
tionalities within a single, large polypeptide (Mazumdar and
Striepen, 2007).
Studies from pathogenic bacteria have confirmed the thera-
peutic value of FAS-II inhibitors (Zhang et al., 2006). These in-
clude triclosan, a microbicide widely used in consumer products.
A highly cited report describing triclosan antimalarial activity
in vitro against P. falciparum and in vivo against the rodent para-
site P. berghei, directed against the pathogenic asexual blood
stages, generated tremendous interest in this compound and
its predicted target, FabI (Surolia and Surolia, 2001). This led to
the structural elucidation of the P. falciparum FabI (PfFabI; Plas-
moDB gene ID PFF0730c) homotetramer, to which triclosan:
NAD+ adducts bind in the active site, and propelled structure-
guided efforts to develop novel antimalarials based on triclosan
(Freundlich et al., 2007; Muralidharan et al., 2003; Perozzo568 Cell Host & Microbe 4, 567–578, December 11, 2008 ª2008 Elset al., 2002). Here, we report our investigations into a series of
analogs designed to improve on the antimalarial properties of
triclosan and our ensuing studies that focused on the biological
role of FabI.
RESULTS
Triclosan Activity against Plasmodium Asexual
Blood Stages Does Not Correlate with Its Inhibition
of Purified Recombinant FabI
We initiated a structure-guided medicinal chemistry program to
improve the potency of triclosan by modifying substituents
around its diaryl ether scaffold. This led us to synthesize 80 ana-
logs (Figure 1A), for which only a single position was modified to
reduce the likelihood of creating off-target activity. These analogs,
grouped by the carbon position that was modified (see Figure 1B
inset; detailed in Table S1 in the Supplemental Data), were evalu-
ated for their inhibition of cultured P. falciparum asexual blood-
stage parasites (3D7 and Dd2 lines), and separately for inhibition
of purified PfFabI enzyme. Activities were compared against tri-
closan, which yielded mean IC50 values of 1.8 and 2.1 mM against
the 3D7 and Dd2 lines and an EC50 value of 73 nM against purified
PfFabI. Individual analog series showed substantial differences in
their inhibitory activities (Figure 1A). The 20-position analog series
afforded the most potent inhibitors in the parasite assays, yet
showed minimal inhibition of PfFabI. Modifications at the 40- or
5-position afforded a few modest improvements in efficacy,
mostly against PfFabI, whereas changes at the 4- or 6-position
generally produced less potent inhibitors. We also noted that
compound series with similar mean potencies against PfFabI
(e.g., the 40- and 5-position analogs) exhibited nearly 10-fold
differences in their mean antiparasitic activities. Further analysis
revealed a lack of a significant association between enzyme and
parasite inhibition, as evidenced by the Pearson r2 values of
0.13 and 0.15 obtained by plotting these data for 3D7 and Dd2, re-
spectively (Figure 1B; data not shown). While chemical properties
such as membrane permeability and solubility might obscure
close whole-cell and enzyme correlations for on-target com-
pounds, our data nonetheless raiseddoubts that triclosananalogs
acted against asexual blood-stage parasites by inhibiting PfFabI.
In parallel with these studies, we re-evaluated the in vivo
efficacy of triclosan. A previous report had documented that
4 days of subcutaneous injections of triclosan at 3 mg/kg/day
could suppress P. berghei parasitemia by 75%, and that injec-
tions with doses of 38 mg/kg/day cured the infected mice with
100% efficacy (Surolia and Surolia, 2001). We tested both per
oral (PO) and subcutaneous (SC) routes of triclosan, adminis-
tered over a range of 16–512 mg/kg/day for 3 days with a twice
daily divided dose, to mice infected 3 days prior with P. berghei
(KBG-173 line). Parasitemias were recorded on day 6 postinfec-
tion (i.e., 1 day after the last dose of triclosan) and were 61%
or 57% (for PO or SC, respectively) in control (infected and
placebo-treated) mice. Increasing the triclosan concentrations
from 16 to 128 mg/kg/day caused a dose-dependent decrease
in parasitemias, to a minimum of 27% or 13% with 128 mg/kg/
day triclosan administered PO or SC, respectively (Figure 1C).
Higher doses failed to further suppress the parasitemias.
Assessment of survival showed that all control mice died by
days 10 (PO) or 12 (SC) (Figures 1D and 1E). Oral administrationevier Inc.
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A Key Role for FabI in Plasmodium Liver StagesFigure 1. Triclosan Displays In Vitro Activity against P. falciparum that Does Not Correlate with Inhibition of FabI and Is Less Effective in
Curing Rodent Malaria Than Previously Reported
(A) Inhibitory activity of subclasses of triclosan analogs against P. falciparum lines and purified PfFabI enzyme.
(B) Log scale scatter plot of the activity of triclosan and its analogs against P. falciparum 3D7 parasites and purified PfFabI, showing the Pearson r2 goodness of fit
value. The inset shows triclosan (5-chloro-2-(2,4-dichlorophenoxy)phenol) with carbon atoms numbered where substitutions were made.
(C) Percent parasitemias plotted for the groups of mice receiving varying doses of triclosan, administered either PO or SC twice daily for 3 days. Mean values
(± SEM) were calculated from groups of 7–8 mice tested on two separate occasions.
(D and E) Kaplan-Meier survival curves for the groups receiving daily triclosan doses as indicated.of 64 mg/kg/day triclosan yielded a slight extension in survival
times,and doses of 128 or 256 mg/kg/day produced 30% survival
rates measured at day 31. Increasing the dose to 512 mg/kg/day
led to some early mortality and decreased overall survival rates,Cell Hostsuggesting some toxicity. Via the SC route, triclosan was moder-
ately more effective, although survival never exceeded 50%.
In vivo tests with several analogs (compounds 18, 20, 22, 41,
45, and 60 in Table S1), whose in vitropotencies were comparable& Microbe 4, 567–578, December 11, 2008 ª2008 Elsevier Inc. 569
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A Key Role for FabI in Plasmodium Liver StagesTable 1. Recombinant and Wild-Type Parasite Lines Used in This Study
Parasite line Species Recombinant Transfection plasmid Endogenous fabI gene present Selectable marker genea Comment
PffabI(A217V)Dd2 P. falciparum Yes pffabI(A217V)-V5-attP Yes bsd, hdhfr [1]
PffabI(WT)Dd2 P. falciparum Yes pffabI(WT)-V5-attP Yes bsd, hdhfr [2]
Dd2attB P. falciparum Yes None Yes hdhfr [3]
Dd2 P. falciparum No None Yes None [4]
PffabI(A217V)3D7 P. falciparum Yes pffabI(A217V)-V5-attP Yes bsd, hdhfr [1]
PffabI(WT)3D7 P. falciparum Yes pffabI(WT)-V5-attP Yes bsd, hdhfr [2]
3D7attB P. falciparum Yes None Yes hdhfr [3]
3D7 P. falciparum No None Yes None [4]
PfDfabI1 P. falciparum Yes pcam-bsd-DpffabI No bsd [5]
PfDfabI2 P. falciparum Yes pcam-bsd-DpffabI No bsd [5]
PbDfabI P. berghei Yes pLitmus28-DpbfabI No Tgdhfr-ts [6]
PbfabIRec P. berghei Yes pLitmus28-pbfabIRec Yes (reinserted) Tgdhfr-ts [7]
ANKA P. berghei No None Yes None [4]
[1]: Expresses mutant pffabI(A217V)-V5 transgene from calmodulin promoter, integrated into cg6 attB site.
[2]: Expresses wild type pffabI(WT)-V5 transgene from calmodulin promoter, integrated into cg6 attB site.
[3]: Contains attB site integrated into cg6 locus. Parental line for transfection with attP-containing pffabI transgene constructs.
[4]: Wild-type nonrecombinant line.
[5]: Endogenous pffabI locus disrupted by single cross-over homologous recombination, clones 1 and 2.
[6]: Endogenous pbfabI locus deleted by double cross-over homologous recombination.
[7]: Endogenous pbfabI locus replaced with a wild type copy of pbfabI plus the Tgdhfr-ts selection cassette.
a Selection was performed using blasticidin hydrochloride for bsd, WR99210 for hdhfr, and pyrimethamine for Tgdhfr-ts.to triclosan, revealed no improvements over the parent com-
pound (A.A. and D.P.J., unpublished data). We concluded that,
under our experimental conditions, triclosan had reduced anti-
malarial potency in vivo as compared to the earlier report (Surolia
and Surolia, 2001). Furthermore, the in vitro potency of triclosan
analogs did not correlate with their inhibition of FabI enzymatic
activity.
Transgene Expression of a Mutant FabI that Is
Biochemically Resistant to TriclosanDoesNotDecrease
P. falciparum Susceptibility to this Agent
To further investigate the role of FabI in the mode of action of
triclosan, we transfected P. falciparum asexual blood-stage
parasites with plasmids expressing V5 epitope-tagged forms of
pffabI that were either wild-type (WT) or that encoded the
A217V mutation. This mutation was selected because it confers
a 7000-fold decrease in triclosan binding affinity for recombinant
PfFabI (Kapoor et al., 2004). To express these pffabI transgenes,
we selected the calmodulin (PF14_0323) promoter, which is
highly active in asexual blood stages (http://www.PlasmoDB.
org). Integration of these plasmids (named pffabI(A217V)-V5-
attP and pffabI(WT)-V5-attP) (Table 1) into the P. falciparum
genome was achieved using the Bxb1 serine integrase-mediated
attB 3 attP system of recombination, which delivers transgenes
into the attB-marked cg6 locus and results in a genetically and
phenotypically homogeneous population of recombinant para-
site lines (Nkrumah et al., 2006). The transfections, performed
with Dd2attB and 3D7attB parasites, produced the transgenic
lines PffabI(A217V)Dd2, PffabI(WT)Dd2, PffabI(A217V)3D7, and
PffabI(WT)3D7 (Table 1 and Figure S1A). Southern blot analysis
confirmed correct integration of the pffabI transgenic copies
into the cg6-attB site and the predicted organization of the en-
dogenous pffabI locus (Figure S1B; data not shown). Western570 Cell Host & Microbe 4, 567–578, December 11, 2008 ª2008 Elsblot analysis with anti-V5 antibodies revealed the expression of
46 kDa V5-tagged PfFabI proteins in all four lines (Figure S1C).
Immunofluorescence assays with the PffabI(A217V)Dd2 line
showed colocalization of PfFabI-V5 and the apicoplast-resident
ACP in a compartment distinct from the nucleus (stained with
Hoechst 33342) and the mitochondrion (stained with MitoTracker
Red), thus confirming trafficking of V5-tagged PfFabI to the
apicoplast (Figures 2A and 2B). We proceeded to measure the
triclosan susceptibility of our transgenic and parental lines. Re-
sults from drug susceptibility assays showed no significant differ-
ence in either IC50 or IC90 values between recombinant lines
expressing mutant or WT PfFabI (Figure 2C; values provided in
legend).
P. falciparum FabI Is Not Expressed at Detectable
Levels in Asexual Blood-Stage Parasites
Subsequent northern blot experiments detected the presence of
pffabI transcripts only in the transgenic lines (PffabI(A217V)Dd2,
PffabI(WT)Dd2, PffabI(A217V)3D7, and PffabI(WT)3D7) that express
an additional pffabI copy from the highly active mature-stage
calmodulin promoter, and not in the lines expressing endoge-
nous pffabI alone (Dd2attB, Dd2, 3D7attB, and 3D7) (Figure 2D).
We attribute the apparent increase in pffabI transcripts in the
PffabI(A217V)Dd2 and PffabI(A217V)3D7 lines, compared to the
PffabI(WT)Dd2 and PffabI(WT)3D7 lines, to the higher proportions
of mature-stage parasites in the former at the time of RNA
harvest. To confirm the lack of endogenous pffabI expression
at the protein level, we raised rabbit polyclonal antiserum against
purified recombinant PfFabI. Western blot analysis with extracts
of parasites expressing calmodulin promoter-driven PfFabI-V5
showed that the antiserum and monoclonal antibodies against
the V5 epitope tag both detected a 46 kDa protein (Figure 2E).
The anti-PfFabI antiserum did not detect any protein in extractsevier Inc.
Cell Host & Microbe
A Key Role for FabI in Plasmodium Liver StagesFigure 2. Transgenic Expression of Mutant
pffabI Does Not Confer Triclosan Resis-
tance In Vitro
(A and B) Fluorescence microscopy of
PffabI(A217V)Dd2 parasites. Proper targeting of
PfFabI-V5 to the apicoplast was illustrated by co-
localization of the V5 epitope tag of the mutant pro-
tein and ACP. This signal was adjacent to the mito-
chondrion that was visualized using MitoTracker
Red (MT). Scale bar is 5 mm. DIC, differential inter-
ference contrast; HT, Hoechst 33342 nuclear dye;
a-V5 anda-ACP, antibodies to V5 and ACP. Similar
results were obtained with PffabI(WT)Dd2 (data not
shown) and with an earlier transgenic Dd2 line that
expressed GFP-tagged PfFabI from the same
calmodulin promoter (Nkrumah et al., 2006).
(C) Inhibitory activity of triclosan against P. falcipa-
rum lines expressing either mutant or WT PfFabI.
Data were derived from three separate experi-
ments performed in duplicate. Lanes (with mean ±
SEM IC50, IC90 values in mM) 1: PffabI(A217V)
Dd2
(2.8 ± 0.7, 6.9 ± 0.4); 2: PffabI(WT)Dd2 (2.5 ± 0.7;
7.3 ± 0.7); 3: Dd2attB (3.1 ± 0.7, 7.2 ± 0.7); 4: PffabI
(A217V)3D7 (2.1 ± 0.4, 4.2 ± 0.3); 5: PffabI(WT)3D7
(2.0 ± 0.3, 4.5 ± 0.7); 6: 3D7attB (2.1 ± 0.2, 4.8 ± 0.6).
(D) Northern blot analysis showing presence of
pffabI transcripts only in the lines expressing this
transgene from the calmodulin promoter. EtBr,
ethidium bromide. Lanes 1: PffabI(A217V)Dd2; 2:
PffabI(WT)Dd2; 3: Dd2attB; 4: Dd2; 5, PffabI
(A217V)3D7; 6, PffabI(WT)3D7; 7: 3D7attB; 8: 3D7.
ef-1a was used as a loading control.
(E) Evidence that a-PfFabI and a-V5 antibodies
recognize the same protein in asexual blood-
stage parasites expressing calmodulin promoter-
driven PfFabI. Lanes 1 and 3: PffabI(A217V)Dd2;
2: PffabI(WT)Dd2 (these lines express PfFabI with
a V5 epitope).
(F) Western blot analysis showing the detection of
PfFabI only in the lines expressing pffabI trans-
genes from the calmodulin promoter. a-PfERD2
antibodies were used as a loading control. Lanes
1–8 are the same as in (D).of control parasites expressing pffabI from its endogenous
promoter (Figure 2F).
FabI Is Not Required for Normal Propagation
of P. falciparum Asexual Blood-Stage Parasites,
and Its Absence Does Not Alter Parasite
Susceptibility to Triclosan
These findings led us to question whether pffabI is required for
P. falciparum asexual blood-stage growth in vitro. To test this,
we designed a DNA construct (pcam-bsd-DpffabI), which con-
tained an internal region of the pffabI coding sequence (encoding
amino acids 98–295) such that homologous recombination
between this fragment and the endogenous pffabI gene would
separate the full-length sequence into two truncated fragments
(Figure S2A). The upstream fragment lacked the 30 end of the
gene corresponding to amino acids 296–432 (thereby eliminating
thea6–a9 helices andb6–b7 strands thatcontribute to forming the
NADH-binding Rossman fold). The downstream fragment lacked
a promoter and the first 98 amino acids that included the bipartite
targeting sequence predicted to be required for protein trafficking
to the apicoplast (Perozzo et al., 2002). Transfection of culturedCell Host &Dd2 parasites with this knockout construct resulted in the gener-
ation of parasite clones (PfDfabI1 and PfDfabI2), in which thepffabI
gene had been disrupted by single site crossover and plasmid
integration, as confirmed by PCR and Southern blot analyses
(Table 1 and Figures S2B and S2C). Measurements of parasitemia
over a 2-month period revealed equivalent growth rates (averag-
ing 5.0- to 5.6-fold multiplication per 48 hr cycle of RBC invasion,
intracellular development, and egress) between these knockout
clones and parental Dd2. These data demonstrated the nones-
sentiality of pffabI for asexual blood-stage propagation, and im-
plied that the activity of triclosan against these stages could not
result from inhibition of PfFabI. This was confirmed with drug sus-
ceptibility assays that revealed similar triclosan susceptibilities in
PfDfabI1, PfDfabI2, and the parental Dd2 line (mean ± SEM; IC50
values of 2.2 ± 0.2, 2.4 ± 0.3, and 2.1 ± 0.3 mM, respectively,
derived from three separate experiments performed in duplicate).
Deletion ofP. berghei fabI, the pffabIOrtholog, Does Not
Affect Propagation of Blood-Stage Parasites In Vivo
Our P. falciparum in vitro data led us to examine whether this
protein was essential for proliferation of asexual blood stagesMicrobe 4, 567–578, December 11, 2008 ª2008 Elsevier Inc. 571
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rodent malaria model. Comparisons of the amino acid se-
quences of PfFabI and its predicted ortholog in P. berghei,
PbFabI (PB000088.02.0), revealed 62% identity and 74% sim-
ilarity (Figure S3A). Bacterial expression and purification of
PbFabI enabled us to elucidate its structure at 2.5 A˚ resolution.
Superimposing this with the known PfFabI structure (Perozzo
et al., 2002) revealed a nearly identical organization with
each subunit in the tetramer containing nine a helices and
seven b sheets (Figure S3B). Detailed inspection of the active
sites revealed these to be indistinguishable (Figure S3C).
From these studies, we can confidently predict that PbFabI
and PfFabI fulfill the same enzymatic function for Plasmodium
parasites.
We transfected P. berghei ANKA parasites with a DNA
construct termed pLitmus28-DpbfabI. This was designed to
permit double crossover, resulting in complete deletion of the
endogenous pbfabI locus and its replacement by the T. gondii
dihydrofolate reductase-thymidylate synthase (Tgdhfr-ts) select-
able marker that confers resistance to pyrimethamine. From
this transfection, we selected mutant parasites and used limiting
dilution to obtain a clone, termed PbDfabI (Table 1). PCR and
Southern blot analyses confirmed correct integration of the
DNA construct and deletion of the pbfabI coding sequence in
this clone (Figures S4A–S4D). As a ‘‘knockin’’ control, we utilized
a similar double crossover strategy to replace the endogenous
gene with a construct that reinserted a full-length, functional
pbfabI gene under control of the endogenous promoter, as well
as the Tgdhfr-ts selectable marker. This yielded the PbfabIRec
clone, whose recombinant locus was confirmed by PCR and
Southern blot hybridization (Figures S4B–S4D). Measurements
of parasitemia in mice infected with PbDfabI, PbfabIRec, or paren-
Figure 3. PlasmodiumAsexual Blood-Stage
Parasites Modify FAs in the Absence of FabI
(A–D) HPLC analysis of extractable FA p-bromo-
phenacyl esters from in vitro cultures of the
P. falciparum lines PfDfabI1 (A) and Dd2 (B), or
ex vivo cultures of the P. berghei lines PbDfabI
(C) and ANKA (D). Acyl chain lengths are indicated.
CPS, counts per second.
tal ANKA revealed similar rates of prolifer-
ation, calculated to be 4.8 ± 1.4, 5.5 ± 2.2,
and 4.4 ± 1.7 per 24 hr cycle, respectively,
in two comparative experiments with
groups of four mice each (values repre-
sents means ± SD; Figure S4E). These
values were not statistically different
between lines, as determined by Mann-
Whitney tests. Thus, there was no sub-
stantial decrease in asexual blood-stage
in vivo viability upon deletion of pbfabI.
Drug susceptibility assays with P. ber-
ghei asexual blood stages tested ex vivo
showed equivalent triclosan IC50 values
in the PbDfabI, PbfabIRec, and ANKA lines
(means ± SEM of 1.4 ± 0.1, 1.5 ± 0.2, and
1.2 ± 0.1 mM, respectively). Control as-
says with the unrelated antimalarial chloroquine produced IC50
values of 11.0 ± 0.1, 13.0 ± 0.6, and 10.4 ± 0.3 nM in these lines,
respectively. These results, combined with the P. falciparum
studies, conclusively demonstrate that the blood-stage activity
of triclosan is not attributable to inhibition of FabI.
Plasmodium Asexual Blood-Stage Parasites Lacking
FabI Can Produce FA Species
The availability of parasite lines lacking FabI allowed us to deter-
mine whetherPlasmodium asexual blood stages utilize the FAS-II
pathway to synthesize FAs de novo. We incubated synchronized
trophozoite-stage P. falciparum and P. berghei control and fabI
knockout parasites with [14C]-acetate, a radiolabeled FA precur-
sor, then extracted the free FAs that had incorporated this sub-
strate and analyzed them by reversed-phase high performance
liquid chromatography (HPLC). In P. falciparum, this led us to de-
tect radiolabeled C16 and C18 FAs in both the PfDfabI
1 and Dd2
lines (Figures 3A and 3B). Thus, extension of FAs could occur
in the absence of the key FAS-II enzyme FabI. In a separate
experiment, we incubated PfDfabI1 and other P. falciparum lines
with [14C]-acetate, extracted their FAs, and analyzed them by
reversed-phase thin layer chromatography. This confirmed the
production of radiolabeled C16 and C18 independently of FabI
(Figure S2D). We note that these findings are in contrast with
an earlier report thatP. falciparum asexual blood-stage parasites
synthesize C10–C14 FAs (Surolia and Surolia, 2001).
[14C]-acetate incorporation studies with the P. berghei lines
produced evidence of de novo FA elongation with PbDfabI para-
sites, with no visible difference between the PbDfabI and parental
ANKA lines in terms of the lengths of FAs that were produced (Fig-
ures 3C and 3D). In contrast toP. falciparum, the rodent parasites
synthesized FA chain lengths of C12–C24. No radiolabeled FAs572 Cell Host & Microbe 4, 567–578, December 11, 2008 ª2008 Elsevier Inc.
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Experiment Parasites Route Sporozoites Number of infected mice Prepatent period (day)a
1 ANKA Intravenous 1,000 5 of 5 4.8
PbfabIRec Intravenous 1,000 5 of 5 4.6
PbDfabI Intravenous 1,000 2 of 5 8.5
PbDfabI Intravenous 10,000 5 of 5 8.0
2 ANKA Intravenous 1,000 6 of 6 3.7
PbfabIRec Intravenous 1,000 5 of 5 4.0
PbDfabI Intravenous 1,000 1 of 6 8.0
PbDfabI Intravenous 10,000 5 of 5 7.8
3 ANKA Intravenous 1,000 5 of 5 3.8
PbfabIRec Intravenous 1,000 5 of 5 4.0
PbDfabI Intravenous 1,000 2 of 5 8.5
PbDfabI Intravenous 10,000 3 of 5 8.3
4 ANKA Mosquito bite From 20 mosquitoes 5 of 5 4.0
PbfabIRec Mosquito bite From 20 mosquitoes 5 of 5 4.0
PbDfabI Mosquito bite From 20 mosquitoes 4 of 5 9.3
a Represents mean number of days after sporozoite inoculation until microscopic detection of blood stage parasites. Mice were examined for blood
stage infections daily until day 28. Means were calculated only from the mice that developed a patent infection.were observed with rodent or human uninfected RBC controls
(data not shown). These data provide evidence that the two
Plasmodium species differ in the range of FAs that they can
extend de novo, yet they share the common characteristic that
FabI is not required.
P. berghei SPZs Lacking FabI Are Markedly Attenuated
in Their Ability to Progress to Asexual Blood-Stage
Infections
The availability of a P. berghei line (PbDfabI) lacking FabI made it
possible to explore the role of this protein in other stages of the
parasite life cycle. We observed that gametocyte production,
gamete fertilization, and the subsequent development of ooki-
netes and oocysts appeared unaffected by the absence of
FabI, as judged by the similar numbers of oocysts that devel-
oped in Anopheles stephensi mosquitoes fed on mice infected
with the PbDfabI, PbfabIRec, or ANKA lines (data not shown). In
two separate experiments, we observed no difference in the
numbers of oocyst and salivary gland SPZs produced by these
lines (data not shown).
To determine whether FabI plays a role in the infectivity of
SPZs to the mammalian host, salivary gland SPZs were dis-
sected and inoculated into the tail vein of C57BL/6 mice. This
inbred strain of mouse was chosen as it is more susceptible
than other inbred or outbred mouse strains to P. berghei SPZ
infections (Scheller et al., 1994). Experiments were performed
on three separate occasions and were highly reproducible. In-
travenous injections of 1000 ANKA or PbfabIRec SPZs pro-
duced patent blood-stage infections that were microscopically
detectable in 16/16 and 15/15 mice by day 5 (Table 2). In con-
trast, injection of 1000 PbDfabI SPZs produced a blood-stage
infection in only 5/16 mice, with the infected mice showing a
delay in patency of 4 days. Increasing the PbDfabI inoculum
to 10,000 SPZs resulted in patent infections in 13/15 mice,
with those mice again showing an average delay of 4 days
compared to controls.Cell HostWe also assayed the infectivity of SPZs delivered by mosquito
bite to test for any defect in SPZ tissue traversal and migration
from the dermis to the liver (Silvie et al., 2008b). Groups of
20 infected mosquitoes were allowed to feed on each mouse,
with 5 mice tested per P. berghei line. Based on earlier studies,
we estimate that each infected mosquito intradermally delivers
120 SPZs (Medica and Sinnis, 2005), yielding an approximate in-
oculum of 2000 SPZs. Results showed that each mouse infected
with ANKA or PbfabIRec parasites, as well as four of the five mice
infected with PbDfabI SPZs, developed a patent blood-stage in-
fection. However, the latter group showed a 5 day delay (Table 2).
Taken together, the data demonstrate that P. berghei para-
sites lacking FabI produce SPZs that are highly attenuated in
their infectivity to the mammalian host. We note that all ‘‘break-
through’’ PbDfabI asexual blood-stage infections became fulmi-
nant and lethal by days 20–29. This suggests that once PbDfabI
parasites developed into blood stages, they showed no loss of
virulence compared to WT parasites. PCR analysis of break-
through infections confirmed that they resulted from PbDfabI
parasites, and not from contamination with ANKA or PffabIRec
parasites (Figure S4F).
PbDfabI SPZs Typically Fail to Produce Infectious
Mature Liver-Stage Parasites
To investigate the cause of this decreased infectivity of PbDfabI
SPZs, we first examined cell traversal and invasion of hepato-
cytes. The former occurs when SPZs transit through cells prior
to initiating liver-stage development by forming a parasitopho-
rous vacuole inside the invaded cell (Silvie et al., 2008b). In two
independent experiments, rates of cell traversal were similar,
with a mean of 9–13 dextran-positive (i.e., traversed) cells
per field. PbDfabI and PbfabIRec lines were also found to
be equally competent for invasion, with 34%–38% success in
invading Hepa 1-6 cells. We next assessed the maturing liver-
stage parasites. At 24, 36, or 48 hr postinvasion, PbDfabI and
PbfabIRec parasites stained with antibodies specific for the& Microbe 4, 567–578, December 11, 2008 ª2008 Elsevier Inc. 573
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equivalent numbers and developmental stages (data not shown).
We also tested for fabI transcription in these stages. RT-PCR
studies from infected Hepa 1-6 cells harvested 40 hr postinvasion
revealed pbfabI mRNA transcripts in PbfabIRec but not PbDfabI
liver-stage parasites (Figure S4G). These results indicate that
fabI is normally transcribed by liver-stage parasites; however,
the lack of expression in PbDfabI parasites did not affect SPZ
cell traversal, invasion of hepatocytes, or the initial stages of
intrahepatic development.
We proceeded to investigate later stages of liver-stage matura-
tion using the HepG2 hepatoma cell line, which is able to support
SPZ invasion and liver-stage development through to the
production of merozoites that are infectious for RBCs. Immuno-
fluorescence assays (IFAs) with mature hepatic stages were
performed with antibodies that recognize the P. berghei parasite
proteins Exp1 (PB000484.01.0) or MSP1 (PB000172.01.0). Exp1
is expressed throughout trophozoite development and schizog-
ony and is exported into the PVM that separates the parasite
from the host cell cytosol. In late liver stages, the Exp1-positive
PVM is typically observed as a closed circular structure around
the multiplying parasite nuclei (Sturm et al., 2006). In schizont
stages, MSP1 is expressed and becomes integrated into the
PPM. The PPM invaginates around pockets of parasite material
during the cytomere stage and ultimately forms the membrane
of individual merozoites (Sturm et al., 2008).
These antibodies revealed a striking difference between ANKA
and PbDfabI parasites very late in their liver-stage development.
At 60 hr post SPZ invasion of HepG2 cells, 59% of the ANKA par-
asites were found to have developed into an advanced parasite
stage marked by MSP1-positive PPM invaginations (Figures 4A
and S5A). Many of these parasites were observed at the cyto-
mere stage in which the PPM surrounded large groups of
parasite nuclei (see row 2 in Figure S5A). The remaining 41%
of parasites were MSP1 negative, indicating either delayed or
aberrant development. In contrast, almost all PbDfabI liver-stage
parasites (99.5%) were negative for MSP1 staining, despite
having initiated their development inside an Exp1-positive PVM
(Figure 4A). In addition to the lack of MSP1 expression in PbDfabI
parasites, nuclear division was clearly impeded, as evidenced by
the limited number of DAPI-positive parasite nuclei (Figure 4A).
The very few MSP1-positive PbDfabI liver-stage parasites that
we did observe were restricted in size, with minimal PPM invag-
inations (Figures 4A and S5A). In support of this, at 60–65 hr
postinvasion, we recorded no cytomere stage in over 3500
PbDfabI liver-stage parasites, whereas cytomeres were ob-
served in 266 ANKA parasites out of a total of 3366. At these
late stages of parasite development, ANKA parasites began to
degrade the PVM, as evidenced by their lack of the typical
Exp1-positive closed circular structures seen in earlier stages
(Figure S5B). This resulted in the generation of large clusters of
MSP1-positive merozoites that filled the entire hepatocyte cyto-
plasm. Of these PVM-degraded, ANKA-infected cells, 87% con-
tained MSP1-positive merozoites. The remaining 13% were
MSP1 negative, suggesting that these had undergone aberrant
development and had failed to produce viable merozoites
(Figure S5B). In contrast, every PbDfabI parasite that was found
to have a nonintact PVM was MSP1-negative and was not
producing mature merozoites (Figure S5B).574 Cell Host & Microbe 4, 567–578, December 11, 2008 ª2008 ElsAt the 65 hr time point, we also recorded the numbers of
infected cells that had detached from the monolayer into the
culture supernatant. These so-called ‘‘detached cells’’ harbor
merozoites that have been released into the host cell cytoplasm
following normal degradation of the PVM (Sturm et al., 2006). In
three independent experiments, we did not observe a single
detached cell with the PbDfabI parasites. In contrast, detached
cells numbered 210, 236, and 106 with ANKA parasites and
298, 136, and 103 with PbfabIRec parasites (Figure 4B). From
these cultures, we also recorded the number of merosomes,
i.e., the membrane-bound clusters of merozoites devoid of host
nuclei that egress from the infected hepatocytes (Sturm et al.,
2006, 2008). Merosomes were never observed in PbDfabI liver-
stage cultures in any of these three experiments. By comparison,
ANKA parasites produced 69, 174, and 41 merosomes, while
PbfabIRec parasites produced 77, 68, and 13 merosomes,
respectively (Figure 4B). Similar results were obtained in three ad-
ditional experiments that examined liver-stage parasites 70 hr
postinvasion (data not shown), confirming a key role for FabI
during the final maturation of the liver-stage schizont and the
formation of merozoites.
While we never observed PbDfabI merosomes, even after an
extended culture period of 90 hr, we nevertheless recorded rare
instances of MSP1-positive PbDfabI merozoites. We also ob-
served one instance of a cytomere stage at 70 hr postinvasion.
The formation of these few merozoites and their passage into
the blood stream might account for the PbDfabI breakthrough
blood-stage infections observed in vivo.
DISCUSSION
Here we report on the discovery that the FAS-II enzyme FabI
plays a key role in the development of infectious liver-stage
merozoites. Our study reveals a fundamental difference in how
Plasmodium liver and asexual-stage parasites balance de novo
synthesis and salvage of host factors to meet their FA require-
ments for intracellular parasite propagation. For asexual blood
stages, our findings provide evidence against a recent report
of an active FAS-II pathway (Surolia and Surolia, 2001) and in-
stead support an alternate mechanism of FA modification that
appears to act alongside a predominant import pathway.
The asymptomatic liver stage begins with SPZs productively
infecting hepatocytes (Mikolajczak and Kappe, 2006; Prudencio
et al., 2006). Following a prodigious phase of nuclear replication,
parasites enter the cytomere stage, wherein nuclei distribute
peripherally beneath the invaginating inner PPM. Later, the outer
PVM disintegrates, releasing merozoites into the host cell cyto-
plasm. This process in vitro leads to cell detachment, followed
by the destruction of host cell organelles, including the nucleus,
and the formation of a host cell membrane-bounded merosome
that is able to initiate a blood-stage infection (Sturm et al., 2006).
Studies with PbDfabI revealed a striking defect in liver-stage
maturation. Whereas cell traversal, invasion, and initial develop-
ment inside a parasitophorous vacuole proceeded normally, late
PbDfabI liver-stage parasites displayed a pronounced absence
of the MSP1 parasite surface protein in the PPM. Furthermore,
these parasites almost completely failed to develop to the cyto-
mere stage, could not normally degrade their PVM, and exhibited
an impaired development of merozoites. PbDfabI parasites alsoevier Inc.
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A Key Role for FabI in Plasmodium Liver StagesFigure 4. P. berghei PbDfabI Parasites Exhibit a Strongly Impaired Merozoite Development and Fail to Form Detached Cells or Merosomes
(A and B) IFA results of ANKA and PbDfabI liver-stage parasites grown in vitro in HepG2 cells and examined 60 hr postinvasion. Parasites were stained with
antibodies directed to Exp1 (green) or MSP1 (red), and DAPI (blue) was used to label the parasite and host cell nuclei. In (A), representative images of liver-stage
parasites developing within an intact PVM are shown by Exp1 staining as a closed circle around the nuclei. Percentages and numbers of MSP1-positive
or -negative parasites were collated from three independent experiments. Results show that most ANKA parasites (58.9%) developed normally and produced
MSP1-positive merozoites, whereas very few PbDfabI parasites (0.5%) were MSP1 positive. The upper panel shows a cytomere stage with typical membrane
invaginations and arrangements of nuclei close to the PPM. In (B), for ANKA-, PbDfabI-, and PbfabIRec-infected HepG2 cells, the numbers of detached cells and
merosomes were quantified 65 hr postinvasion, in three independent experiments. These revealed a total absence of detached cells and merosomes in PbDfabI
liver-stage cultures. Additional representative images are presented in Figure S5.displayed a near-total lack of cell detachment and merosome
formation (Figures 4 and S5). We posit that this developmental
arrest explains the attenuated infectivity of PbDfabI SPZs, as
illustrated by their substantially delayed progression to blood-
stage infection (Table 2). Residual infectivity was nevertheless
observed, especially with the higher doses of 104 PbDfabI SPZs
that produced blood-stage infections in most mice. These
‘‘breakthrough’’ infections were fulminant and lethal, indicating
that the few parasites that completed their liver-stage develop-
ment were not attenuated for asexual blood-stage growth.
Dr. Stefan Kappe (Seattle Biomedical Research Institute) and
colleagues have observed a similar phenotype of late liver-stageCell Hostarrest upon deletion of the FAS-II gene fabB/F in P. yoelii 17XNL.
Their analysis of infected hepatocytes, obtained in BALB/c mice
inoculated 44 hr prior with fabB/F knockout SPZs, revealed a lack
of MSP1 staining and merozoite formation as well as a defect in
PVM degradation (based on Hep17 expression) when compared
to WT liver-stage parasites. In agreement with our observations,
no attenuation was evident at other life-cycle stages for both
P. yoelii fabB/F knockout parasites and a further knockout line
that carried a deletion of fabZ. In contrast to PbDfabI SPZs, the
P. yoelii fabB/F knockout line failed to produce breakthrough
asexual blood-stage infections, even with an inoculum as
high as 100,000 salivary gland SPZs (S. Kappe, personal& Microbe 4, 567–578, December 11, 2008 ª2008 Elsevier Inc. 575
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the erythrocytic stages of P. berghei ANKA versus P. yoelii
17XNL. P. berghei ANKA parasites are known to rapidly produce
a fulminant, lethal infection starting from low numbers of infected
RBCs. In contrast, P. yoelii 17XNL infections are nonlethal and
can be readily resolved by host immune responses. Alternatively,
these species might differ in their dependence on FAS-II for suc-
cessful liver-stage development.
Taken together, the FAS-II gene disruption data make a
compelling case that de novo FA biosynthesis plays a key role
in the successful production of the thousands of infectious mer-
ozoites produced per infected hepatocyte. While it is possible
that FAS-II provides unique (i.e., unsalvageable) FAs, the detec-
tion of breakthrough infections with PbDfabI suggests that its
role is predominantly to augment levels of salvaged FAs to
meet metabolic demands. Insights into the potential utilization
of FAS-II products are provided by our investigations with
PbDfabI. These parasites revealed a pronounced deficit in their
expression of MSP1, which is anchored to the parasite mem-
brane via GPI moieties. These moieties are enriched in C16:0 (pal-
mitic acid), C18:0 (stearic acid), and C18:1 (oleic acid) (Naik et al.,
2000). How could these be produced by the liver-stage parasite?
Biochemical studies with purified P. falciparum FAS-II enzymes
provide evidence that this pathway produces predominantly
C10–C14 FAs (Sharma et al., 2007). To modify these species
into the saturated and unsaturated FAs found in GPI anchors
would require the further action of elongases and desaturases
(see below), whose activity in liver-stage parasites has been
detected (Tarun et al., 2008). The inability of PbDfabI liver-stage
parasites to form cytomeres and normally degrade their PVM
suggests that FAS-II products might also be incorporated into
neutral glycerolipids, which have been implicated in intracellular
vesicle trafficking, and membrane-resident phospholipids (Pal-
acpac et al., 2004). Likewise, the failure of PbDfabI-infected he-
patocytes to form detached cells suggests that FAS-II products
might contribute to parasite manipulation of the phospholipid
composition of host cell membranes, a mechanism that appears
to subvert immune recognition by liver phagocytes and that
correlates with in vitro cell detachment (Sturm et al., 2006).
This proposed central role of FAs in liver-stage biology agrees
with recent transcriptome data showing that all four P. yoelii
FAS-II genes are highly expressed in liver stages as compared
to SPZs or asexual blood stages (Tarun et al., 2006). Those stud-
ies also revealed upregulation of members of the pyruvate dehy-
drogenase complex, whose production of acetyl-CoA primes the
FAS-II pathway (Mazumdar and Striepen, 2007). These studies
evoke the idea of targeting FAS-II enzymes for the development
of a novel prophylactic antimalarial drug that clears liver-stage
infections before they advance to the pathogenic erythrocytic
stages.
In contrast to the phenotype of late liver-stage arrest observed
upon disruption of the FAS-II pathway, other Plasmodium gene
disruption studies have produced much earlier arrest. Dual dis-
ruption of the P. yoelii genes p36 and p52 (also termed p36p), in-
dividual knockouts of their orthologs in P. berghei, disruption of
the sap1/slarp gene in P. yoelii and P. berghei, and disruption of
the P. berghei uis4 or uis3 genes all produced a developmental
block within 24–48 hr postinvasion (Aly et al., 2008; Silvie et al.,
2008a; references therein). Of the genetically attenuated SPZs,576 Cell Host & Microbe 4, 567–578, December 11, 2008 ª2008 Elsthose that did not cause breakthrough asexual blood-stage
infections were found to elicit complete protective immunity
against challenge with nonattenuated SPZs. We did not perform
similar studies because of the finding that PbDfabI SPZs could
produce breakthrough parasitemias. Nevertheless, when com-
pared to the other knockout lines, the delayed demise of PbDfabI
liver-stage parasites provides a greater window of antigen pre-
sentation, suggesting a potentially enhanced degree of immuno-
genicity (Jobe et al., 2007). Furthermore, given that the human
parasite P. falciparum has a prodigious growth phase inside
hepatocytes, on the order of 10,000–30,000 merozoites per
infected cell as compared to 8,000–10,000 per hepatocyte for
P. berghei and P. yoelii (Verhave and Meis, 1984), one might pre-
dict that the inability to produce sufficient levels of FAs through
de novo synthesis could be severely detrimental for P. falcipa-
rum. Interestingly, the P. berghei PVM-resident protein UIS3
has been shown to bind L-FABP (liver-fatty acid binding protein),
a key mediator of cellular uptake and transport of the FAs and
lipid species that are abundant in hepatocytes (Furuhashi and
Hotamisligil, 2008). This leads us to hypothesize that the disrup-
tion of liver-stage FA de novo synthesis and import might yield
potent, genetically attenuated, pre-erythrocytic-stage vaccines
in Plasmodium species, including P. falciparum.
Though the FAS-II pathway appears vitally important to liver-
stage parasites, the analysis of our PfDfabI and PbDfabI lines ar-
gues against the earlier hypothesis that this pathway is required
for asexual blood-stage propagation (Surolia et al., 2004). An
alternative explanation of our data would be that another enoyl
ACP-reductase might have compensated for the loss of FabI
and thereby restored FAS-II functionality to theDfabI lines during
their life cycle. Our bioinformatic search for alternate bacterial
enoyl-ACP reductases (FabK, FabL, and FabV) (Massengo-
Tiasse and Cronan, 2008) fail to identify any orthologs in Plasmo-
dium, although this does not rule out their potential existence.
Nonetheless, the blood and liver-stage phenotypes we observe
with our DfabI lines have also been observed by Stefan Kappe
and colleagues with transgenic P. yoelii parasites that lack
fabB/F or fabZ (personal communication). Again, we have not
found paralogs of these genes through bioinformatic searches
of Plasmodium genomes. Our data, therefore, are consistent
with a lack of requirement for the FAS-II pathway in asexual
blood-stage parasites and support earlier evidence that these
stages rely on salvage pathways for the bulk of their FA require-
ments (Vial and Ancelin, 1992).
In a remarkable body of work, Mi-Ichi et al. (Mi-Ichi et al., 2007,
2006) found that several combinations, including C16:0/C18:0/
C18:2,n-6 or C16:0/C18:1,n-9/C18:2,n-6, were sufficient to replace hu-
man serum or Albumax in malaria culture medium and permitted
robust parasite growth for over 6 months. These various FAs are
the predominant species present in human plasma and infected
RBCs (Mi-Ichi et al., 2006). As per earlier reports (Krishnegowda
and Gowda, 2003; Vial and Ancelin, 1992), these authors ob-
served that salvaged FAs are predominantly incorporated in an
unmodified form into parasite lipids. In addition, they observed
FA modification via elongation or desaturation processes. This
included the production of C16:0 and C18:0 from exogenous
[14C]-C14:0 and [
14C]-C16:0, respectively, and desaturation of
C18:0 to C18:1 (Mi-Ichi et al., 2006). In agreement with these
findings, we also observed C16 and C18 FAs when incubatingevier Inc.
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difference between lines harboring or lacking FabI (Figures 3
and S2D). We also observed no such incorporation in control
uninfected RBCs.
P. falciparum asexual blood-stage production of radiolabeled
C16 and C18 FAs might involve elongases, three of which are en-
coded by this genome (Lee et al., 2007). The presence of four dis-
tinct elongases in the P. berghei genome might explain why this
species was found to produce C12–C24 FAs (Figure 3). These
ER-resident enzymes are responsible in mammals for producing
very long chain FAs (RC18) and, in trypanosomes, producing
C10–C18 FAs (Jakobsson et al., 2006; Lee et al., 2006). P. falcipa-
rum asexual blood stages are also capable of modifying FAs via
desaturation of C16:0 and C18:0 at the n-9 position, presumably
via their D9 desaturase (PFE0555w) (Mi-Ichi et al., 2006). Another
crucial step in the intraerythrocytic modification of imported host
FAs may involve acyl-CoA synthetase enzymes, which activate
acyl chains for entry into FA synthesis, desaturation, and elonga-
tion pathways. Members of this gene family are present in 4–12
copies in Plasmodium species, and biochemical assays have
shown 20-fold higher acyl-CoA synthetase activity in infected ver-
sus uninfected RBCs (Bethke et al., 2006; Vial and Ancelin, 1992).
FabI has been extensively studied as a candidate drug target
for asexual blood-stage parasites. Yet our data now argue
against the therapeutic potential of this target, and indeed the
entire FAS-II pathway, during erythrocytic infection. These data
imply that, contrary to earlier suppositions (Ralph et al., 2004;
Surolia et al., 2004), asexual blood-stage parasites do not
require FAS-II activity in the apicoplast. Focusing on FabI, our
transgene overexpression and gene disruption studies demon-
strate that this is not the target of the antimalarial activity of triclo-
san (Figures 2, S1, S2, and S4), despite an earlier report of its
inhibition of FA biosynthesis in asexual blood-stage parasites
and its high affinity for purified enzyme (Perozzo et al., 2002;
Surolia and Surolia, 2001). These data agree with studies of Try-
panosoma brucei parasites that discounted FabI as the target of
triclosan and proposed nonspecific membrane perturbation as
an alternate mode of action (Lee et al., 2007). Our studies
nevertheless find that triclosan has activity against Plasmodium
asexual blood-stage parasites and is efficacious in vivo (Figure 1),
albeit at concentrations substantially higher than previously re-
ported (Surolia and Surolia, 2001). Further studies are required
to elucidate how triclosan acts upon asexual blood-stage para-
sites. In these stages, it is now clear that exogenous FAs are
essential. We propose that therapeutic strategies to interfere
with FA processes in asexual blood-stage parasites should focus
on import and subsequent modification, presumably mediated
by elongases, the D9 desaturase, and acyl CoA-synthetases.
This contrasts with liver-stage parasites where interference with
FAS-II offers novel perspectives for prophylactic intervention.
EXPERIMENTAL PROCEDURES
Parasite Propagation
P. falciparum lines (Table 1) and P. berghei ANKA parasites were propagated
as described in the Supplemental Data. All experiments involving rodents were
conducted in fully accredited animal facilities and were approved by the Insti-
tutional Animal Care and Use Committees of Columbia University, the Albert
Einstein College of Medicine, the New York University Medical Center, the
University of Miami, and the Bernhard Nocht Institute for Tropical Medicine.Cell HostParasite In Vitro and In Vivo Drug Susceptibility Assays
The synthesis of triclosan analogs has been previously described (Freundlich
et al., 2007; references therein). For enzyme inhibition assays, the reaction
mixtures contained 50 nM PfFabI, 400 mM NADH, and 40 mM NAD+, and
were initiated with 300 mM butyryl-CoA. Inhibition of PfFabI-mediated
butyryl-CoA reduction was assessed spectrophotometrically by measuring
the oxidation of NADH to NAD+ at 340 nm (Freundlich et al., 2007). EC50 values
represent the analog concentration that inhibited maximal PfFabI activity by
50%. Inhibition of P. falciparum in vitro or P. berghei ex vivo parasite growth
was measured using [3H]hypoxanthine assays, and the IC50 values were calcu-
lated using linear regression (see Supplemental Data). All compounds were
tested in duplicate on at least two separate occasions. For in vivo efficacy
studies, CD-1 mice were infected intraperitoneally on day 0 with 53 104P. ber-
ghei asexual blood-stage parasites. Triclosan (Vita-Pharm; Valhalla, NY) was
administered on days 3, 4, and 5 after infection as two divided doses daily,
spaced 6 hr apart, delivered either PO or SC. Parasitemias were determined
from Giemsa-stained smears of tail blood, collected on day 6 and twice
a week thereafter until day 31 (see Supplemental Data).
Plasmid Constructs, Parasite Transfections, Nucleic Acid
and Protein Analyses, Immunofluorescence Assays,
and Structural Elucidation of PbFabI
These are detailed in the Supplemental Data. Primers are listed in Table S2,
and transfection plasmids and parasite lines are listed in Table 1.
FA Extraction and HPLC Analysis
P. falciparum- or P. berghei-infected RBCs were labeled with [14C]-acetate
(10 mCi/ml) for 6 hr or 24 hr, respectively, at 37C. Parasite pellets were
obtained by saponin lysis and washed twice to remove host cell components,
and the FAs were analyzed by reversed-phase HPLC (see Supplemental Data).
P. berghei Infection of Mosquitoes, Sporozoite Invasion and Cell
Traversal Assays, and Analysis of Liver-Stage Development
Experimental conditions are detailed in the Supplemental Data.
Determination of P. berghei Prepatent Periods in Mice
To determine the in vivo infectivity of mutant and control parasite lines, naive
C57BL/6 mice were injected intravenously with 1,000 or 10,000 P. berghei sal-
ivary gland SPZs or subjected to the bite of 20 infected mosquitoes that were
allowed to probe for 6 min. Asexual blood-stage infection was determined by
Giemsa-stained blood smears prepared on days 3–28 after SPZ inoculation.
SUPPLEMENTAL DATA
The Supplemental Data includes Supplemental Experimental Procedures,
Supplemental References, five figures, and two tables and can be found
online at http://www.cell.com/cellhostandmicrobe/supplemental/S1931-
3128(08)00368-5.
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